Noom Med review

What it is

Noom, Inc. is the Princeton, New Jersey company behind the Noom weight-loss app, known for psychology-based lessons and coaching. Noom Med is its clinical arm. Under its terms, Noom isn't a healthcare provider: independent clinical partners do the prescribing, lab work and pharmacy services, and Noom provides the platform and the program. Its clinical lead is Dr. Jeffrey Egler, Noom's Chief Medical Officer, a family and lifestyle medicine physician. For compounded medication, Noom says it uses state-regulated pharmacies that follow USP standards, sources active ingredients from suppliers on the FDA's green list, has each batch tested by a third party, and will send a Certificate of Analysis for your batch on request. It doesn't name the pharmacies. The page displays a LegitScript badge image without a verifiable seal number, so check LegitScript's own lookup.

How it works

You complete an online health survey, and a clinician reviews it, mostly asynchronously through chat, though some programs offer video visits. Noom verifies every patient's identity, asks for a full-body photo before treatment, and requires a comprehensive medical intake. If you're prescribed, brand-name drugs are coordinated through your pharmacy and insurance, Zepbound vials can come through LillyDirect, and compounded medication ships to your home. After that, you have unlimited access to your clinician for dose changes and refills. Noom uses gradual "SmartDose" titration and starts low. The app side includes the GLP-1 Companion with lessons, tracking, a one-to-one coach, a community, and a Muscle Defense program to limit muscle loss. Noom's claims that members lose 37% or 48% more weight with the program come from its own user data, one of them a retrospective study of self-reported weights, not from randomized trials, and a footnote says the link with app use doesn't prove cause.

Pricing transparency

Noom combines its program and clinical services into one subscription price, which varies by route. For brand-name drugs, the Noom Med subscription is $39 to start and then $129 a month, and medication isn't included. Your cost for the drug depends on your insurance, or you can buy Zepbound vials from $299 a month through LillyDirect. The compounded programs include medication and are billed differently. The Microdose GLP-1Rx Program starts with a three-week subscription and four weeks of medication from $79 plus tax, then $179 a month plus tax for a 12-week subscription (a Noom blog post gives $199). The dual-action program starts at $149, then $299 a month on the same 12-week basis. Because the monthly figure is charged against a 12-week term, budget for the full term rather than a single month. Plans renew automatically; cancel in your account before 11:59 p.m. Eastern on the day before the next billing date. Noom doesn't refund partly used billing periods except at its discretion, and California residents can cancel within three business days of signing up for a refund. Several plans are FSA/HSA eligible.

Branded vs compounded

Brand-name Wegovy (pen and pill), Zepbound, Ozempic, Mounjaro and Foundayo, generic liraglutide, metformin, and compounded semaglutide and tirzepatide in microdose and standard programs. Wegovy, Zepbound and Foundayo are FDA-approved for weight management, and Noom's own page cites the 15% and 20% average losses in the Wegovy and Zepbound trials, which it labels as applying to the branded drugs only. Ozempic and Mounjaro are approved for type 2 diabetes, and metformin isn't approved for weight loss, as Noom notes. Noom states that its compounded semaglutide is made in an FDA-registered facility but hasn't been reviewed by the FDA for safety, efficacy or quality. Its microdose program uses doses below those tested in the major trials, and its "up to 17 pounds in 60 days" figure comes from self-reported user data. A search of the FDA warning-letter database for Noom returned no letter.

Pros and watch-outs

The evidence behind what Noom Med prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• What the semaglutide weight-loss trials actually showed

  STEP 1, STEP 4, and SELECT — the efficacy, the rebound, and the cardiovascular signal, read straight from the primary literature.

• Zepbound vs Wegovy: what the trials actually show

  Zepbound (tirzepatide) leads on weight loss in the one head-to-head trial; Wegovy (semaglutide) has the cardiovascular-outcomes approval. An honest comparison.

• “Microdosing” GLP-1 drugs: a trend, not a protocol — what the evidence says

  Sub-therapeutic semaglutide and tirzepatide is spreading fast. The pharmacology is clear, the honest part is clearer: efficacy is dose-related, and no trial has tested intentional microdosing.

• Orforglipron: the oral non-peptide GLP-1, and what the trials actually show

  A once-daily small-molecule GLP-1 pill with no food restrictions — from Phase 2 proof of concept to the Phase 3 read-outs. The evidence, graded.

How Noom Med compares

A few alternatives worth a look, depending on what you’re optimizing for.

• Found

  Compounded GLP-1 with the drug included, and insurance for the visits

  See Found →
• Willow

  Buyers who want every dose priced and the pharmacies named, and will pay more for it

  See Willow →
• Ro

  A polished, well-resourced end-to-end program

  See Ro →

More GLP-1 telehealth reviews: RxSpan MD · Telos RX · Hims · Henry Meds · Mochi Health · LifeMD